Patent 11964948 was granted and assigned to Actinium Pharmaceuticals on April, 2024 by the United States Patent and Trademark Office.
Provided are new bifunctional chelators for use in the manufacture of radiolabeled targeting agents for therapeutic or diagnostic use. Also provided are conjugates of the new bifunctional chelators with various cancer antigen targeting agents.